Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [21] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 270 - 286
  • [22] Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    Chong, V.
    EYE, 2016, 30 (02) : 270 - 286
  • [23] Real-world outcomes of Ranibizumab treatment for Diabetic Macular Oedema
    Patrao, Namritha Valerie
    Antao, Sheelah
    Sim, Dawn A.
    Sivaprasad, Sobha
    Andrews, Richard
    Hamilton, Robin
    Egan, Catherine A.
    Tufail, Adnan
    Hykin, Philip G.
    Rajendram, Ranjan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [24] Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
    Vasileios E. Konidaris
    Konstantinos T. Tsaousis
    Rossella Anzidei
    Guillermo de la Mata
    Alexander J. Brent
    Ophthalmology and Therapy, 2018, 7 : 387 - 395
  • [25] Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
    Konidaris, Vasileios E.
    Tsaousis, Konstantinos T.
    Anzidei, Rossella
    de la Mata, Guillermo
    Brent, Alexander J.
    OPHTHALMOLOGY AND THERAPY, 2018, 7 (02) : 387 - 395
  • [26] Real-world utilization of ranibizumab in wetage related macular degeneration patients from Canada
    Devenyi, Robert
    Maberley, David
    Sheidow, Tom G.
    Tourville, Eric
    Brunck, Lynne
    Berger, Alan R.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2016, 51 (02): : 55 - 57
  • [27] SWITCHING TO BIOSIMILAR INFLIXIMAB: REAL-WORLD DATA FROM THE SOUTHAMPTON BIOLOGIC THERAPIES REVIEW SERVICE
    Holroyd, Christopher
    Parker, Lucy
    Bennett, Sarah
    Zarroug, Jalaa
    Underhill, Caron
    Davidson, Brian
    Armstrong, Ray
    Harvey, Nick
    Dennison, Elaine
    Cooper, Cyrus
    Edwards, Christopher J.
    RHEUMATOLOGY, 2016, 55 : 60 - 61
  • [28] Ranibizumab vs. Aflibercept in diabetic Macular Edema - Real-World Data at 1 Year
    Bitzer, Michaela
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2020, 237 (08) : 924 - +
  • [29] Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study
    Pearce, Ian
    Parikh, Soumil
    Macfadden, Wayne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [30] Patient perspectives from a real-world adalimumab biosimilar switching program
    Choon, X. Y.
    Moore, A.
    Sharma, E.
    Anderson, S.
    Gecse, K.
    Mawdsley, J.
    Ray, S.
    Dart, R.
    Irving, P.
    Samaan, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1761 - i1761
12345